• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Coral

    Sacituzumab Govitecan Plus Pembro Shows Durable Benefit in mTNBC

    ASCO

    Plinabulin Combo Shows Durable Benefit in NSCLC at ASCO 2026

    GLOBENEWSWIRE

    FDA Expands Agilent PD-L1 Test Approval Across Four Cancers

    PRESS RELEASE

    Modern And Merck Unveil 5-Year Data On Intismeran Autogene

    ACCESSWIRE

    D3 Bio: Elisrasib Shows Landmark First-Line KRAS NSCLC Efficacy

    PR NEWSWIRE

    Sac-TMT + Pembro for 1L PD-L1+ NSCLC Published in The Lancet

    PR NEWSWIRE

    Immatics IMA401 Bispecific Data at ASCO, Published in Nature

    GLOBENEWSWIRE

    TiumBio Presents Tosposertib + Pembro Phase 2a Data at ASCO

    PR NEWSWIRE

    Immunocore`s Brenetafusp Phase 1 Data Updated in Melanoma

    GLOBENEWSWIRE

    Sac-TMT Phase 3 OptiTROP-Lung05 Data at ASCO; Published in Lancet

    PR NEWSWIRE

    FDA Grants Breakthrough Designation to Calderasib in KRAS NSCLC

    BUSINESSWIRE

    Citius Oncology Presents LYMPHIR Phase 1 Combo Data at ASCO 2026

    PR NEWSWIRE

    Adcendo & MSD to Evaluate ADCE-T02 + KEYTRUDA in Solid Tumors

    PR NEWSWIRE

    Merck Gets CHMP Backing for Keytruda + Padcev in Bladder Cancer

    PHARMIWEB

    OSE Turn Up Heat on Ovarian Cancer With Ph2 Win, Support Keytruda

    FIERCE BIOTECH

    Pliant Therapeutics Presents at 2026 ASCO Annual Meeting

    GLOBENEWSWIRE

    Ficerafusp Alfa Plus Pembrolizumab Shows 3-Year Survival in HNSCC

    GLOBENEWSWIRE

    Asher Biotherapeutics Presents CD8 Pipeline Data at ASCO 2026

    GLOBENEWSWIRE

    Eisai Deepens LENVIMA Evidence Across Indications at ASCO 2026

    PR NEWSWIRE

    BioInvent to Host KOL Event on BI-1808 for Ovarian Cancer

    ACCESSWIRE

    Exelixis, Merck Collaborate on Phase 3 STELLAR-316 CRC Trial

    BUSINESSWIRE

    Mestag Therapeutics Doses First Patient with MST-0312 in Phase I

    GLOBENEWSWIRE

    Microbiotica MB097 Phase 1b MELODY-1 Trial Positive in Melanoma

    PRESS RELEASE

    BeyondSpring to Present Poster at 2026 ASCO Meeting

    GLOBENEWSWIRE

    India’s Counterfeit Drug Crisis & Role of AI

    EXPRESSPHARMA

    HCW Biologics: HCW11-040 Prevents Bronchopulmonary Dysplasia

    GLOBENEWSWIRE

    Pyxis Oncology Reports First Quarter 2026 Financial Results

    GLOBENEWSWIRE

    Merck Showcases Long-Term Oncology Data and Pipeline at ASCO 2026

    BUSINESSWIRE

    BioInvent`s BI-1808 Enhances Immune Response In Advanced CTCL

    ACCESSWIRE

    Erasca Partners Merck to Test ERAS-0015 with Keytruda

    GLOBENEWSWIRE

    Caris: Whole Exome TMB Boosts Survival vs Gene Panels

    PR NEWSWIRE

    Inhibrx Combo Outperforms Keytruda in Tumor Shrinkage

    PR NEWSWIRE

    Inhibrx to Host Webcast on INBRX-106 HexAgon First-Line HNSCC

    PR NEWSWIRE

    China NMPA Accepts sac-TMT Plus Pembro sNDA in PD-L1+ NSCLC

    PR NEWSWIRE

    Samsung Bioepis` Pembrolizumab Biosimilar SB27 Meets PK Endpoints

    INDPHARMAPOST

    Alpha Tau to Present Alpha DaRT Head & Neck Data at AHNS

    GLOBENEWSWIRE

    KEYTRUDA SC Subcutaneous Form Now Available Across UK

    FIRSTWORD PHARMA

    Merck & Co.`s Keytruda posts $8B in Q1 as Qlex picks up steam

    FIRSTWORD PHARMA

    Pliant Therapeutics Initiates Phase 1B Trial For PLN-101095

    GLOBENEWSWIRE

    Merck Halts TROP ADC Development as Keytruda Clock Ticks

    BIOSPACE

    Bioinvent International AB: Interim Report January - March 2026

    PHARMIWEB

    Merck, Rivals Eye Inhibrx Experimental Drug Tied to Keytruda

    REUTERS

    Hope Rises For Rare Gynaecological Clear Cell Cancer

    FIRSTWORD PHARMA

    Labcorp Introduces Fda-Approved Ovarian Cancer Diagnostic

    PR NEWSWIRE

    Merck’s Welireg Triplet Fails Phase 3 in first-line kidney Cancer

    FIERCE PHARMA

    Moderna To Present Data At 2026 ASCO Conference

    PHARMIWEB

    Bioinvent To Showcase BI-1808 And Keytruda In Ovarian Cancer

    PHARMIWEB

    FDA Grants Priority Review for Keytruda + Padcev in MIBC Cancer

    PHARMIWEB

    FDA Grants Priority Review for PADCEV + Keytruda in MIBC Cancer

    PR NEWSWIRE

    Moderna To Unveil Mrna-4359 Cancer Therapy Data At AACR 2026

    PHARMIWEB

    Kainova Expands DT-7012 Trial to Europe and Doses First Patient

    PHARMIWEB

    EC Approve KEYTRUDA + Paclitaxel ± Bevacizumab for Ovarian Cancer

    PHARMIWEB

    Adagene & Incyte to Trial Muzastotug + TGFßR2xPD-1 in CRC

    GLOBENEWSWIRE

    Ivonescimab Shows QoL Benefits in Chemo-Free NSCLC: ELCC

    PR NEWSWIRE

    Pliant Therapeutics To Present PLN-101095 Phase 1 Trial Results

    GLOBENEWSWIRE

    Adagene To Showcase Muzastotug (ADG126) At 2026 (AACR) Meeting

    GLOBENEWSWIRE

    Varsetatug Masetecan Shows Promise in Late-Line Colorectal Cancer

    GLOBENEWSWIRE

    Immutep`s Ph. 3 Failure Surprises Analysts, Sinks Stock

    FIERCE BIOTECH

    Citius: LYMPHIR Plus Pembrolizumab Shows Promise in Gyn Cancers

    PR NEWSWIRE

    Keytruda Hangs On To Best Seller Crown As Glp-1s Gain Ground

    BIOSPACE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.